Nephros (NEPH) vs Regentis Biomaterials (RGNT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nephros is the larger company by market cap ($35.7 million vs $11.9 million), about 3.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEPH | RGNT |
|---|---|---|
| Share price | $3.29 | $1.70 |
| Market cap | $35.73M | $11.94M |
| 1-day change | +2.81% | +4.29% |
| YTD return | -32.58% | -74.78% |
| 1-year return | -36.24% | — |
| 5-year return | -57.60% | — |
| P/E ratio (TTM) | 21.93 | — |
| Forward P/E | 15.67 | — |
| EPS (TTM) | $0.15 | $-2.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $15.50 |
| 52-week low | $2.66 | $1.23 |
| Distance from 52-week high | -48.75% | -89.03% |
| Analyst consensus | none | none |
| Avg. price target upside | +89.97% | +488.24% |
| Average volume | 27.59K | 76.78K |
| Shares outstanding | 10.86M | 7.02M |
| Employees | 36 | — |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Instruments & Supplies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nephros is about 3.0 times larger than Regentis Biomaterials by market value ($35.73M vs $11.94M).
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Healthcare · Medical Instruments & Supplies · 36 employees
About Regentis Biomaterials
RGNT stock →Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.
Healthcare · Medical Instruments & Supplies
NEPH vs RGNT FAQ
Which is bigger, Nephros or Regentis Biomaterials?
Nephros (NEPH) is larger, with a market capitalization of $35.73M compared with $11.94M for Regentis Biomaterials (RGNT).
Are Nephros and Regentis Biomaterials in the same industry?
Yes. Both are classified in the Medical Instruments & Supplies industry within the Healthcare sector.